Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Nice.

Scientists have enlisted the exotic properties of graphene, a one-atom-thick layer of carbon, to function like the film of an incredibly sensitive camera system in visually mapping tiny electric fields in a liquid. Researchers hope the new method will allow more extensive and precise imaging of the electrical signaling networks in our hearts and brains.

The ability to visually depict the strength and motion of very faint electrical fields could also aid in the development of so-called lab-on-a-chip devices that use very small quantities of fluids on a microchip-like platform to diagnose disease or aid in drug development, for example, or that automate a range of other biological and chemical analyses. The setup could potentially be adapted for sensing or trapping specific chemicals, too, and for studies of light-based electronics (a field known as optoelectronics).

“This was a completely new, innovative idea that graphene could be used as a material to sense electrical fields in a liquid,” said Jason Horng, a co-lead author of a study published Dec. 16 in Nature Communications that details the first demonstration of this graphene-based imaging system.

Read more

Herbs treating Tuberculosis.

A centuries-old herbal medicine, discovered by Chinese scientists and used to effectively treat malaria, may help treat tuberculosis and slow the evolution of drug resistance.

A new study shows the ancient remedy artemisinin stopped the ability of TB-causing bacteria, known as Mycobacterium tuberculosis, to become dormant. This stage of the disease often makes the use of antibiotics ineffective.

The study is published in the journal Nature Chemical Biology.

Read more

A column on #transhumanism I did for Flaunt:

Are you ready for the future? A Transhumanist future in which everyone around you—friends, family, and neighbors—has dipped into the cybernetic punch bowl? This is a future of contact lenses that see in the dark, endoskeleton artificial limbs that lift a half-ton, and brain chip implants that read your thoughts and instantly communicate them to others. Sound crazy? Indeed, it does. Nevertheless, it’s coming soon. Very soon. In fact, much of the technology already exists. It’s being sold commercially at your local superstore or being tested in laboratories right now around the world.

We’ve all heard about driverless test cars on the roads and how doctors in France are replacing people’s hearts with permanent robotic ones, but did you know there’s already a multi-billion dollar market for brainwave-reading headsets? Using electroencephalography (EEG) sensors that pick up and monitor brain activity, NeuroSky’s MindWave can attach to Google Glass and allow you to take a picture and post it to Facebook and Twitter just by thinking about it. Other headsets allow you to play video games on your iPhone with only your thoughts as well. In fact, a few months ago, the first mind-to-mind communication took place. A researcher in India projected a thought to a colleague in France, and using their headsets, they understood each other. Telepathy went from science fiction to reality, just like that.

The history of cybernetics—sometimes used to describe robotic implants, prosthetics, and cyborg-like enhancements in the human being and its experience—has come a long way since scientists began throwing around the term in the 1950s. What a difference a generation or two makes. Today a thriving pro-cyborg medical industry is setting the stage for trillion-dollar markets that will remake the human experience. Five million people in America suffer from Alzheimer’s, but a new surgery that involves installing brain implants is showing promise in restoring people’s memory and improving lives. The use of medical and microchip implants, whether in the brain or not, are expected to surge in the coming years. NBC News recently reported that many Americans will likely have chip implants within a decade’s time. It’s truly a new age for humans.

Standing proud at the forefront of all this change is the fascinating biohacker culture, where extreme inventors and innovators are leading the way by sticking RFID tracking chips in their bodies, permanent wireless headphones near their eardrums, and magnets in their fingers.

Read more

A new genetic disease has been discovered that could play a key role in devastating brain conditions such as Alzheimer’s and Parkinson’s, opening up the possibility of new forms of treatment.

A 47-year-old Canadian woman, who had been having difficulty walking and balancing since she was 28, was found to have a new genetic disease after 10 known conditions were ruled out, according to a paper in the journal Nature by an international team of researchers.

The disease causes an over-reaction by the body’s natural repair system. An enzyme, known as PARP1, goes into over-drive, ultimately causing the deaths of brain cells.

Read more

Senescent cell removal is the first true rejuvenation therapy to treat one of the aging processes and with human clinicial trials in the next 18 months these are some very exciting times. Here is yet another study showing natural compounds can be used in combination with drugs to kill senescent cells.

Today’s open access research paper outlines the discovery of yet another new candidate drug for the selective destruction of senescent cells. This is an increasingly popular research topic nowadays. Senescent cells perform a variety of functions, but on the whole they are bad news. Cells become senescent in response to stresses or reaching the Hayflick limit to replication. They cease further division and start to generate a potent mix of signals, the senescence-associated secretory phenotype or SASP, that can provoke inflammation, disarray the surrounding extracellular matrix structures, and change behavior of nearby cells for the worse. Then they destroy themselves, or are destroyed by the immune system — for the most part at least. This is helpful in wound healing, and in small doses helps to reduce cancer incidence by removing those cells most at risk of becoming cancerous. Unfortunately a growing number of these cells linger without being destroyed, more with every passing year, and their presence eventually causes significant dysfunction. That in turn produces age-related disease, frailty, and eventually death. Senescent cells are not the only root cause of aging, but they provide a significant contribution to the downward spiral of health and wellbeing, and even only their own would eventually produce death by aging.

The beneficial aspects of senescent cells seem to require only a transient presence, so the most direct approach to the problem presented by these cells is to destroy them every so often. Build a targeted therapy capable of sweeping senenscent cells from tissues, and make it efficient enough to keep the count of such cells low. That is the way to prevent senescent cells form contributing to age-related disease. Working in mice, researchers have produced results such as functional rejuvenation in aged lungs and extended life span through the targeted destruction of senescent cells. Since perhaps only a few percent of the cells in old tissue are senescent, this targeted destruction can be accomplished with few side-effects beyond those generated by off-target effects of the medication itself.

Read more

A new biomarker for Alzheimers could improve the patient outcome and allow for earlier treatment.

An enzyme found in the fluid around the brain and spine is giving researchers a snapshot of what happens inside the minds of Alzheimer’s patients and how that relates to cognitive decline.

Iowa State University researchers say of the enzyme, autotaxin, significantly predict impairment and Type 2 diabetes. Just a one-point difference in autotaxin levels — for example, going from a level of two to a three — is equal to a 3.5 to 5 times increase in the odds of being diagnosed with some form of memory loss, said Auriel Willette, an assistant professor of food science and human nutrition at Iowa State.

Autotaxin, often studied in cancer research, is an even stronger indicator of Type 2 diabetes. A single point increase reflects a 300 percent greater likelihood of having the disease or pre-diabetes. The results are published in the Journal of Alzheimer’s Disease. Willette and Kelsey McLimans, a graduate research assistant, say the discovery is important because of autotaxin’s proximity to the .

Read more

New study provides deeper insight into the immune system.

In a bid to better understand the gene expression patterns that control T cell activity, researchers at the La Jolla Institute for Allergy and Immunology mapped genome-wide changes in chromatin accessibility as T cells respond to acute and chronic virus infections. Their findings, published in the Dec. 20, 2016 issue of Immunity, shed light on the molecular mechanisms that determine the fate of T lymphocytes and open new approaches to clinical intervention strategies to modulate T cell activity and improve immune function.

“Identifying the different factors that determine different T cell states and therefore their function helps us understand if T cells will be able or not to fight viral infections or tumor growth, and if they will be able or not to provide long-term protection,” says the study’s first author James Scott-Browne, a postdoctoral fellow in the laboratory of Anjana Rao, a professor in the Division of Signaling and Gene Expression. “We may be able to revert the exhaustion phenotype of T cells and render them better able to fight tumors or chronic viral infections such as HIV, or generate better memory cells in response to vaccines.”

When viruses invade or cells turn malignant, the immune system mobilizes a small cohort of naïve or immature CD8 T cells, a crucial subdivision of the immune system charged with killing virus-infected and . Upon activation, they mature and proliferate exponentially into highly specific effector T cells that eliminate virus-infected or otherwise compromised cells. After their job is done, most effector T cells die leaving behind only a small contingent of memory T cell that confer long-term protection.

Read more

Stanford University’s amazing new regenerative medicine facility where the impossible is becoming possible.

The 25,000-square-foot facility, which opened last September, puts Stanford at the forefront of one of medicine’s most important and promising trends: regenerative medicine, which aims to refurbish diseased or damaged tissue using the body’s own healthy cells.

“We’re curing the incurable,” said laboratory director David DiGiusto, who holds a doctorate.

Critics complain that no one makes anything in Silicon Valley anymore except mobile apps and plug-in cars, a decades-long gripe that dates back to the shuttering of chip fabrication plants.

Read more

Decline of the immune system is one of the areas SENS are working on, with just over a week left for the Winter Fundraiser and Triple donation match now is the time to support their work!

Immunosenescence is a key process in aging and rejuvention or replacement of the thymus which gradually wastes away as we age exposing us to pathogens is an important step in dealing with age-related diseases. SENS is working on these problems so if you want to see solutions please consider donating to our Winter Fundraiser today on the link below:

http://www.sens.org/donate

“As we age and are exposed to persistent pathogens, especially cytomegalovirus, ever more of the T cell population becomes specialized in ways that remove the ability to deal with new threats. A flood of new immune cells would help to restore the balance, and in recent years researchers have demonstrated that transplanting a young and active thymus into an old mouse does in fact restore measures of immune function, and extends life span as well.”

Read more

Light therapy kills cancer in new no surgery, no chemo approach.

A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new UCL-led phase III clinical trial in 413 patients. The trial was funded by STEBA Biotech which holds the commercial license for the treatment.

The new , ‘vascular-targeted photodynamic therapy’ (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate. The research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.

“These results are excellent news for men with early localised prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,” says lead investigator Professor Mark Emberton, Dean of UCL Medical Sciences and Consultant Urologist at UCLH. “This is truly a huge leap forward for , which has previously lagged decades behind other solid cancers such as breast cancer. In 1975 almost everyone with breast cancer was given a radical mastectomy, but since then treatments have steady improved and we now rarely need to remove the whole breast. In prostate cancer we are still commonly removing or irradiating the whole prostate, so the success of this new tissue-preserving treatment is welcome news indeed.”

Read more